Trending...
- Chicago Man Accused of Attempting to Disarm Naperville Police Officer
- M Film Lab Launches Spring 2025 Screenwriting Lab: Tales of Identity & Imagination
- REV Entertainment Announces Purchase Of The Kane County Cougars
CHICAGO, Oct. 31, 2024 ~ Amphix Bio, a leading company in the development of regenerative medicine therapies, has announced that it has been awarded a $1 million Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation (NSF). The grant will be used to scale up manufacturing methods for the company's innovative platform technology, which is based on supramolecular peptide therapeutics that signal the patient's own cells to initiate regenerative processes.
The main focus of this grant is to develop manufacturing technology that will enable Amphix Bio to produce an off-the-shelf implant for spinal fusion surgeries. This product has recently been designated as a Breakthrough Device by the FDA for its potential in treating back pain caused by degenerative disc disease. In its Phase I project, Amphix Bio successfully developed new manufacturing methods for its bone regeneration therapy and created a moldable, putty-like formulation that showed promising results in large animal models. With this Phase II grant, the company aims to further scale up production of their therapeutic peptides, develop new manufacturing methods for the putty formulation, and complete biocompatibility testing.
More on illi News
According to Amphix Bio co-founder and CEO Nick Sather, PhD, "We are grateful to the NSF for this Phase II funding and are excited to advance our manufacturing capabilities to bring the supramolecular therapeutics platform into the clinic." He also added that their technology has the potential to offer a simpler and safer solution for treating debilitating back pain without any side effects associated with traditional methods such as harvesting autograft tissue or using recombinant proteins.
In preparation for clinical trials, Amphix Bio has recently expanded its team with new hires in manufacturing and operations. Dr. Iwona Maciagiewicz joined the company last year and brings extensive experience in biotech manufacturing including small molecules, biologics, and diagnostic devices. Dr. Hussain Sangji also joined Amphix Bio in 2024 from the Boston Consulting Group (BCG) and will be leading strategy and operations projects for major global Biopharma and MedTech companies.
More on illi News
This grant brings Amphix Bio's total SBIR funding to $1.25 million. In addition to the SBIR grant, the company has also received non-dilutive funding from the Illinois Science and Technology Coalition to support innovation in the state. These grants will further expand Amphix Bio's collaborations with Northwestern University. The company will be working closely with Dr. Wellington Hsu, MD, and Dr. Erin Hsu, PhD, professors of orthopedic surgery at Northwestern's Feinberg School of Medicine, who will oversee pre-clinical testing and advise on the clinical development of the product.
With this new grant funding and strengthened team, Amphix Bio is well-positioned to advance their innovative regenerative medicine therapies towards clinical trials and potentially revolutionize the treatment of back pain caused by degenerative disc disease.
The main focus of this grant is to develop manufacturing technology that will enable Amphix Bio to produce an off-the-shelf implant for spinal fusion surgeries. This product has recently been designated as a Breakthrough Device by the FDA for its potential in treating back pain caused by degenerative disc disease. In its Phase I project, Amphix Bio successfully developed new manufacturing methods for its bone regeneration therapy and created a moldable, putty-like formulation that showed promising results in large animal models. With this Phase II grant, the company aims to further scale up production of their therapeutic peptides, develop new manufacturing methods for the putty formulation, and complete biocompatibility testing.
More on illi News
- Announcing The Must-Read Crypto Playbook Of 2025!
- Etan Polinger Officially Recognized As New Mexico's First Certified Ai Consultant
- Expert Law Attorneys Nominates 2025 Personal Injury Firms
- Chicago: Statement From Mayor Brandon Johnson on The Board Of Education Budget Amendment
- The Ripple Effect Arts Leverages Social Media to Showcase the Benefits of Magic Magnesium Spray, Driving 200% Audience Growth
According to Amphix Bio co-founder and CEO Nick Sather, PhD, "We are grateful to the NSF for this Phase II funding and are excited to advance our manufacturing capabilities to bring the supramolecular therapeutics platform into the clinic." He also added that their technology has the potential to offer a simpler and safer solution for treating debilitating back pain without any side effects associated with traditional methods such as harvesting autograft tissue or using recombinant proteins.
In preparation for clinical trials, Amphix Bio has recently expanded its team with new hires in manufacturing and operations. Dr. Iwona Maciagiewicz joined the company last year and brings extensive experience in biotech manufacturing including small molecules, biologics, and diagnostic devices. Dr. Hussain Sangji also joined Amphix Bio in 2024 from the Boston Consulting Group (BCG) and will be leading strategy and operations projects for major global Biopharma and MedTech companies.
More on illi News
- Chicago: Mayor Johnson To Host High School Basketball State Champs at City Hall
- Chicago: ICYMI: Chair Ervin Implores CPS to Follow Through on Commitment to Pension Payment
- America Is Being Ripped Off: It's Time To Take Action Against Fraud & Foreign Exploitation
- Independence Title Honored for Excellence in Fraud Prevention by Stewart Title
- Dentaluxe's New Website Launch!
This grant brings Amphix Bio's total SBIR funding to $1.25 million. In addition to the SBIR grant, the company has also received non-dilutive funding from the Illinois Science and Technology Coalition to support innovation in the state. These grants will further expand Amphix Bio's collaborations with Northwestern University. The company will be working closely with Dr. Wellington Hsu, MD, and Dr. Erin Hsu, PhD, professors of orthopedic surgery at Northwestern's Feinberg School of Medicine, who will oversee pre-clinical testing and advise on the clinical development of the product.
With this new grant funding and strengthened team, Amphix Bio is well-positioned to advance their innovative regenerative medicine therapies towards clinical trials and potentially revolutionize the treatment of back pain caused by degenerative disc disease.
Filed Under: Business
0 Comments
Latest on illi News
- Forum Continues Top Customer Satisfaction Streak for 2024
- Fray Fitness Launches Redesigned Website to Enhance Customer Experience
- Rampage Jackson and Rashad Evans Face Off At Press Conference At The Palms Casino Resort in Las Vegas on March 20, 2025
- Leading the Industry: Green Office Partner Featured on ENX Magazine's Front Page
- Drone Light Shows Become the Must-Have Entertainment Trend for Events and Venues
- Multi-Million Dollar Contracts and Key Partnerships for Cybersecurity Solutions in the Rapidly Growing Market Nearing $200 Billion Annually $CYCU
- Unveil Hydrogen-Powered Maritime Innovation at H2Hub Summit
- Brookline Family Dentistry Updates Website URL for a Stronger Brand Identity
- Major Defense Contractor, Satellite and Multiple Deployable Tech Companies Partnering with Ascent Solar Technologies, Inc: Stock Symbol: ASTI
- Rosann Santos Ofrece el Programa Repensando el Síndrome del Impostor™
- Criptlán Partners with Top Capital and Technology Teams to Drive the Future of the Digital Economy
- From Sea to the Site: The Evolution of the Shipping Container From the Water to the Worksite
- Chicago Small Business Leaders Launch 'Draft Rahm for President 2028' PAC
- Inbound Lead Generation for Security Companies in 2025: The Key to Sustainable Growth
- FIRST EDUCATION-FOCUSED ADVERTISING CAMPAIGN CENTERED ON 'THE SCIENCE BEHIND THE PLANT'
- Chicago Man Accused of Attempting to Disarm Naperville Police Officer
- Frame Up Now Leverages Cyntexa and Salesforce to Fuel Their Operations & Power Up Lead Conversion
- M Film Lab Launches Spring 2025 Screenwriting Lab: Tales of Identity & Imagination
- Castilla y León Wines Roadshow from Spain Returns to the East Coast in 2025
- TFL Tech Inc. Launches New & Improved Website